代谢紊乱相关肾病与糖尿病肾病的新潜在治疗靶点
代谢综合征增加慢性肾脏病发生及进展风险,并使个体易患糖尿病从而增加糖尿病肾病(DKD)易感性。当前DKD治疗已扩展至肾素-血管紧张素-醛固酮系统抑制剂、钠-葡萄糖共转运蛋白2抑制剂、非甾体盐皮质激素受体拮抗剂和胰高血糖素样肽-1受体激动剂,但DKD仍持续存在和进展。本小型综述聚焦DKD和代谢相关肾病临床前模型中的若干新兴靶点,并简要概述其肾脏保护机制相关通路。
要点
- 代谢综合征增加CKD发生和进展风险,并易感糖尿病进而增加DKD易感性。
- 当前DKD治疗包括RAAS抑制剂、SGLT2抑制剂、非甾体MRA和GLP-1RA,具显著肾脏保护作用。
- DKD仍持续进展,需针对其潜在病理生理机制开发新治疗策略。
核心结论
- DKD在现有治疗下仍持续存在和进展,亟需针对潜在病理生理机制的新型治疗策略。
研究设计与样本
- 本小型综述聚焦DKD和代谢相关肾病临床前模型中的新兴治疗靶点。
主要发现
- 当前DKD治疗已扩展至RAAS抑制剂、SGLT2抑制剂、非甾体MRA和GLP-1RA,具有显著肾脏保护作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Individuals with metabolic syndrome are at an increased risk of developing chronic kidney disease or accelerating the progression of preexisting chronic kidney disease. Furthermore, such individuals are predisposed to developing diabetes, increasing their susceptibility to diabetic kidney disease (DKD). Current DKD treatments have expanded to include renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists, which confer significant renoprotection. Nevertheless, DKD continues to persist and progress, underscoring the need for the development of novel therapeutic strategies that additionally target the underlying pathophysiological mechanisms in DKD. This mini review highlights several emerging targets from preclinical models of DKD and metabolic-associated kidney disease and provides a brief overview of the pathways involved in their mechanisms of renoprotection.
引用
- Li X, He JC, Lee K, et al. New potential therapeutic targets of metabolic disorder-associated kidney disease and diabetic kidney disease. Kidney Int. 2025. PMID: 41139023. doi:10.1016/j.kint.2025.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。